Glucose cotransporter-2 inhibitors on mortality and hospitalization in heart failure patients: a comprehensive meta-analysis.
Signal observed in meta-analysis of 15 RCTs (n=28,484) showing SGLT2 inhibitors reduced all-cause mortality by 14% and heart failure hospitalization by 26% across heart failure phenotypes. Evidence suggests additional benefits including NT-proBNP reduction (-168 pg/mL), improved LVEF (+3.8%), and enhanced diuretic efficiency (+480 mL/day). Worth noting these findings were consistent regardless of diabetes status or ejection fraction category, though data remains primarily adult-focused without pediatric congenital heart disease specificity.
The consistency and magnitude of benefit confirm a class effect and support SGLT2 inhibitors as foundational therapy for heart failure across all ejection fraction categories.
Relevance: Directly addresses heart failure research interest with mortality and functional outcomes data, though SGLT2 inhibitors are not in current formulary and findings lack pediatric congenital heart disease context.